Patents by Inventor Timothy J. Toner

Timothy J. Toner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol.nef and modifications
    Publication number: 20040101957
    Abstract: First generation adenoviral vectors and associated recombinant adenovirus-based HIV vaccines which show enhanced stability and growth properties and greater cellular-mediated immunity are described within this specification. These adenoviral vectors are utilized to generate and produce through cell culture various adenoviral-based HIV-1 vaccines which contain HIV-1 gag, HIV-1 pol and/or HIV-1 nef polynucleotide pharmaceutical products, and biologically relevant modifications thereof. These adenovirus vaccines, when directly introduced into living vertebrate tissue, preferably a mammalian host such as a human or a non-human mammal of commercial or domestic veterinary importance, express the HIV-1 Gag, Pol and/or Nef protein or biologically modification thereof, inducing a cellular immune response which specifically recognizes HIV-1.
    Type: Application
    Filed: March 14, 2003
    Publication date: May 27, 2004
    Inventors: Emilio A. Emini, Rima Youil, Andrew J. Bett, Ling Chen, David C. Kaslow, John W. Shiver, Timothy J. Toner, Danilo R. Casimiro
  • Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
    Patent number: 6733993
    Abstract: First generation adenoviral vectors and associated recombinant adenovirus-based HIV vaccines which show enhanced stability and growth properties and greater cellular-mediated immunity are described within this specification. These adenoviral vectors are utilized to generate and produce through cell culture various adenoviral-based HIV-1 vaccines which contain HIV-1 gag, HIV-1 pol and/or HIV-1 nef polynucleotide pharmaceutical products, and biologically relevant modifications thereof. These adenovirus vaccines, when directly introduced into living vertebrate tissue, preferably a mammalian host such as a human or a non-human mammal of commercial or domestic veterinary importance, express the HIV1-Gag, Pol and/or Nef protein or biologically modification thereof, inducing a cellular immune response which specifically recognizes HIV-1.
    Type: Grant
    Filed: September 14, 2001
    Date of Patent: May 11, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Emilio A. Emini, Rima Youil, Andrew J. Bett, Ling Chen, David C. Kaslow, John W. Shiver, Timothy J. Toner, Danilo R. Casimiro
  • Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-Gag, Pol, Nef and modifications
    Publication number: 20030044421
    Abstract: First generation adenoviral vectors and associated recombinant adenovirus-based HIV vaccines which show enhanced stability and growth properties and greater cellular-mediated immunity are described within this specification. These adenoviral vectors are utilized to generate and produce through cell culture various adenoviral-based HIV-1 vaccines which contain HIV-1 gag, HIV-1 pol and/or HIV-1 nef polynucleotide pharmaceutical products, and biologically relevant modifications thereof. These adenovirus vaccines, when directly introduced into living vertebrate tissue, preferably a mammalian host such as a human or a non-human mammal of commercial or domestic veterinary importance, express the HIV1-Gag, Pol and/or Nef protein or biologically modification thereof, inducing a cellular immune response which specifically recognizes HIV-1.
    Type: Application
    Filed: September 14, 2001
    Publication date: March 6, 2003
    Inventors: Emilio A. Emini, Rima Youil, Andrew J. Bett, Ling Chen, David C. Kaslow, John W. Shiver, Timothy J. Toner, Danilo R. Casimiro